Our analysis of a previously reported dataset [35] indicated that expression of LUZP2 mRNA was significantly higher in primary tumors compared to normal prostate tissues, but intriguingly was lower again in metastatic CRPC compared to primary PC (Figure 6C and 6D). The gene discussed is LUZP2; the disease is pachyonychia congenita.